Completed PHASE1 INTERVENTIONAL 2-arm
NCT00834561
Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions
Randomized, Two-Way Crossover, Single-Dose, Fasting Bioequivalence Study of Lamotrigine 1 x 200 mg Tablet
Sponsor: Teva Pharmaceuticals USA
Conditions
Healthy
Interventions
Lamictal® Lamotrigine
Updated 1 time since 2024 Last updated: Aug 15, 2024 Started: Jan 31, 2002 Primary completion: Feb 28, 2002 Completion: Feb 28, 2002
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Healthy and is currently completed. Teva Pharmaceuticals USA leads this study, which shows 1 recorded version since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Completed — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Teva Pharmaceuticals USA
Data source: Teva Pharmaceuticals USA
For direct contact, visit the study record on ClinicalTrials.gov .